Compare Abbott Laboratories (ABT) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs QUALCOMM, Inc. — how do they compare? Abbott Laboratories trades at $95.16 (market cap $166.94B), while QUALCOMM, Inc. trades at $185.01 (market cap $192.85B). The key difference: QUALCOMM, Inc. is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | QCOM | |
|---|---|---|
Market Cap | $166.94B | $192.85B |
Sector | Health | Technology |
52-Week High | $136.62 | $251.10 |
52-Week Low | $82.57 | $124.07 |
Enterprise Value | $193.69B | $198.32B |
Dividend Yield | 2.63% | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Qualcomm (QCOM) trades at $186.48, up 5.8% in the last 24 hours, reflecting strong momentum. The stock exhibits a bearish technical signal but has consistently beaten earnings expectations in recent quarters. Revenue for 2025 reached $44.28 billion, with a net income margin of 22.31%, though this represents a decline from the previous year. The company is actively diversifying into AI, automotive, and data centers, as highlighted at recent industry events like COMPUTEX 2026.
The outlook is mixed; analyst consensus is a 'Buy' with a $221.21 price target, indicating potential upside, but near-term risks include margin pressures and intense competition in the PC and smartphone chip markets. The stock's valuation, with a P/E of 20.05, appears reasonable relative to growth prospects, but investors must weigh the diversification strategy against persistent market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
